JP2015038135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015038135A5 JP2015038135A5 JP2014214604A JP2014214604A JP2015038135A5 JP 2015038135 A5 JP2015038135 A5 JP 2015038135A5 JP 2014214604 A JP2014214604 A JP 2014214604A JP 2014214604 A JP2014214604 A JP 2014214604A JP 2015038135 A5 JP2015038135 A5 JP 2015038135A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- kit
- risedronate
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 208000020084 Bone disease Diseases 0.000 claims 3
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 3
- 229940089617 risedronate Drugs 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 230000001186 cumulative effect Effects 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000007888 film coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 235000015097 nutrients Nutrition 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/897,897 | 2004-07-23 | ||
| US10/897,897 US20050070504A1 (en) | 2001-12-21 | 2004-07-23 | Risedronate compositions and their methods of use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013169220A Division JP5761274B2 (ja) | 2004-07-23 | 2013-08-16 | リセドロネート組成物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015038135A JP2015038135A (ja) | 2015-02-26 |
| JP2015038135A5 true JP2015038135A5 (enExample) | 2015-04-09 |
| JP5910698B2 JP5910698B2 (ja) | 2016-04-27 |
Family
ID=34958880
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007522476A Expired - Lifetime JP5377852B2 (ja) | 2004-07-23 | 2004-09-25 | リセドロネート組成物およびその使用方法 |
| JP2013169220A Expired - Lifetime JP5761274B2 (ja) | 2004-07-23 | 2013-08-16 | リセドロネート組成物およびその使用方法 |
| JP2014214604A Expired - Lifetime JP5910698B2 (ja) | 2004-07-23 | 2014-10-21 | リセドロネート組成物およびその使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007522476A Expired - Lifetime JP5377852B2 (ja) | 2004-07-23 | 2004-09-25 | リセドロネート組成物およびその使用方法 |
| JP2013169220A Expired - Lifetime JP5761274B2 (ja) | 2004-07-23 | 2013-08-16 | リセドロネート組成物およびその使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050070504A1 (enExample) |
| EP (1) | EP1776123A1 (enExample) |
| JP (3) | JP5377852B2 (enExample) |
| KR (2) | KR20070038115A (enExample) |
| CN (1) | CN101146542A (enExample) |
| AR (1) | AR046036A1 (enExample) |
| AU (2) | AU2004322703B2 (enExample) |
| BR (1) | BRPI0418973A (enExample) |
| CA (1) | CA2564898A1 (enExample) |
| IL (1) | IL180907A0 (enExample) |
| IS (1) | IS8597A (enExample) |
| MA (1) | MA28778B1 (enExample) |
| MX (1) | MX2007000967A (enExample) |
| NO (1) | NO20071058L (enExample) |
| NZ (1) | NZ552799A (enExample) |
| PE (1) | PE20060144A1 (enExample) |
| RU (1) | RU2007103306A (enExample) |
| TW (1) | TWI351286B (enExample) |
| WO (1) | WO2006022755A1 (enExample) |
| ZA (1) | ZA200701308B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2469779C (en) * | 2001-12-21 | 2008-02-12 | The Procter & Gamble Company | Method for the treatment of bone disorders |
| CN1939314A (zh) * | 2002-05-10 | 2007-04-04 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗和预防骨质疏松症的二膦酸 |
| SI1596870T2 (sl) * | 2002-12-20 | 2011-07-29 | Hoffmann La Roche | Formulacija z visokim odmerkom ibandronata |
| US20080286359A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| AU2011218625B2 (en) * | 2004-05-24 | 2014-03-20 | Theramex HQ UK Limited | Dosage forms of risedronate |
| US7645459B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
| US20080287400A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
| US7473684B2 (en) * | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
| CA2924200C (en) * | 2005-10-12 | 2017-09-05 | Proventiv Therapeutics, Llc | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency |
| GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
| GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
| GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
| KR100844256B1 (ko) | 2007-03-23 | 2008-07-07 | 코오롱제약주식회사 | 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법 |
| JP2011529902A (ja) * | 2008-07-31 | 2011-12-15 | 味の素株式会社 | リセドロネートまたはその塩の低投与量形態 |
| KR101379664B1 (ko) * | 2008-09-23 | 2014-04-02 | 한림제약(주) | 리세드론산 또는 그의 염 및 비타민 ｄ를 포함하는 약학 조성물 |
| KR101102364B1 (ko) | 2009-09-18 | 2012-01-03 | 한림제약(주) | 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물 |
| PT106978A (pt) * | 2013-05-31 | 2014-12-02 | Tecnimede Sociedade Tecnico Medicinal S A | Composição sólida oral contendo ácido ibandrónico e vitamina d |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA777769A (en) * | 1963-03-18 | 1968-02-06 | H. Roy Clarence | Substituted methylene diphosphonic acid compounds and detergent compositions |
| IT1201087B (it) * | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| FR2531088B1 (fr) * | 1982-07-29 | 1987-08-28 | Sanofi Sa | Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation |
| IL77243A (en) * | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
| US4761406A (en) * | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
| DE3623397A1 (de) * | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| CA1339805C (en) * | 1988-01-20 | 1998-04-07 | Yasuo Isomura | (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active |
| CA1336328C (en) * | 1988-04-11 | 1995-07-18 | Walter G. Leonard | Method of increasing bone density in humans |
| US4922007A (en) * | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| US5227506A (en) * | 1989-09-06 | 1993-07-13 | Merck & Co., Inc. | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors |
| NL8902727A (nl) * | 1989-11-06 | 1991-06-03 | Philips Nv | Objecthouder voor ondersteuning van een object in een geladen deeltjesbundelsysteem. |
| DK0650361T3 (da) * | 1992-06-30 | 1999-06-23 | Procter & Gamble Pharma | Sammensætninger til behandling af arthritis, hvilke sammensætninger indeholder phosphonater og NSAID'er |
| US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
| US6008206A (en) * | 1994-09-21 | 1999-12-28 | Merck & Co., Inc. | Sodium alendronate preparation for local administration |
| US6750216B2 (en) * | 1996-03-08 | 2004-06-15 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
| US5730715A (en) * | 1996-06-14 | 1998-03-24 | Becton Dickinson And Company | Method for the iontophoretic administration of bisphosphonates |
| GB2324726A (en) * | 1997-05-01 | 1998-11-04 | Merck & Co Inc | Combination Therapy for the Treatment of Osteoporosis |
| ES2226128T3 (es) * | 1997-06-11 | 2005-03-16 | THE PROCTER & GAMBLE COMPANY | Comprimido revestido con una pelicula para una seguridad del tracto gastrointestinal superior mejorada. |
| US5994329A (en) * | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| US6432932B1 (en) * | 1997-07-22 | 2002-08-13 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| US6015801A (en) * | 1997-07-22 | 2000-01-18 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| US6331533B1 (en) * | 1998-11-16 | 2001-12-18 | Merck & Co., Inc. | Method for inhibiting dental resorptive lesions |
| US6225801B1 (en) * | 1999-01-14 | 2001-05-01 | Lucent Technologies Inc. | Article comprising electronic circuits and devices with magnetically programmable electrical resistance |
| JP2001253827A (ja) * | 2000-02-15 | 2001-09-18 | Pfizer Prod Inc | 骨粗鬆症を治療するための組成物および方法 |
| US6468559B1 (en) * | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
| HU228400B1 (en) * | 2000-06-20 | 2013-03-28 | Novartis Ag | The use of bisphosphonates for treatment of osteoporosis |
| US6593310B1 (en) * | 2000-11-21 | 2003-07-15 | Arthropharm Pty. Ltd. | Treatment of osteoporosis |
| CA2468687A1 (en) * | 2001-12-13 | 2003-06-26 | Merck & Co., Inc. | Liquid bisphosphonate formulations for bone disorders |
| CN1939314A (zh) * | 2002-05-10 | 2007-04-04 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗和预防骨质疏松症的二膦酸 |
| US20040188316A1 (en) * | 2003-03-26 | 2004-09-30 | The Procter & Gamble Company | Kit for pharmaceutical use |
-
2004
- 2004-07-23 US US10/897,897 patent/US20050070504A1/en not_active Abandoned
- 2004-09-25 WO PCT/US2004/031975 patent/WO2006022755A1/en not_active Ceased
- 2004-09-25 BR BRPI0418973-6A patent/BRPI0418973A/pt not_active Application Discontinuation
- 2004-09-25 JP JP2007522476A patent/JP5377852B2/ja not_active Expired - Lifetime
- 2004-09-25 MX MX2007000967A patent/MX2007000967A/es unknown
- 2004-09-25 CA CA002564898A patent/CA2564898A1/en not_active Abandoned
- 2004-09-25 RU RU2007103306/14A patent/RU2007103306A/ru unknown
- 2004-09-25 EP EP04789250A patent/EP1776123A1/en not_active Ceased
- 2004-09-25 CN CNA2004800436570A patent/CN101146542A/zh active Pending
- 2004-09-25 NZ NZ552799A patent/NZ552799A/en not_active IP Right Cessation
- 2004-09-25 AU AU2004322703A patent/AU2004322703B2/en not_active Withdrawn - After Issue
- 2004-09-25 KR KR1020077001602A patent/KR20070038115A/ko not_active Ceased
- 2004-09-25 KR KR1020087021196A patent/KR20080083219A/ko not_active Ceased
- 2004-09-29 AR ARP040103537A patent/AR046036A1/es unknown
- 2004-09-30 PE PE2004000960A patent/PE20060144A1/es not_active Application Discontinuation
- 2004-11-30 TW TW093136901A patent/TWI351286B/zh not_active IP Right Cessation
-
2007
- 2007-01-23 IL IL180907A patent/IL180907A0/en unknown
- 2007-01-24 IS IS8597A patent/IS8597A/is unknown
- 2007-02-01 MA MA29645A patent/MA28778B1/fr unknown
- 2007-02-14 ZA ZA200701308A patent/ZA200701308B/en unknown
- 2007-02-22 NO NO20071058A patent/NO20071058L/no not_active Application Discontinuation
-
2011
- 2011-03-02 AU AU2011200905A patent/AU2011200905A1/en not_active Abandoned
-
2013
- 2013-08-16 JP JP2013169220A patent/JP5761274B2/ja not_active Expired - Lifetime
-
2014
- 2014-10-21 JP JP2014214604A patent/JP5910698B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015038135A5 (enExample) | ||
| JP2013231087A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2015523407A5 (enExample) | ||
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| JP2015057451A5 (enExample) | ||
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| JP2016106150A5 (enExample) | ||
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| BR112014001297A2 (pt) | procedimento para a fabricação de uma composição farmacêutica em forma de tabletes de liberação prolongada contendo pirfenidona e sua aplicação na regressão da insuficiência renal crônica, na contratura capsular mamária e na fibrose hepática humanas | |
| AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
| JP2016147915A5 (enExample) | ||
| BR112018012870A2 (pt) | métodos e composições para o tratamento de transtornos relacionados à crise | |
| JP2015537009A5 (enExample) | ||
| ME02474B (me) | Terapijski režimi | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| MX2020012377A (es) | Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades. | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| NZ611026A (en) | Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2016505050A5 (enExample) | ||
| HRP20190211T1 (hr) | Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti | |
| HRP20161796T1 (hr) | Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. |